Bristol-Myers Squibb's Oncology Revenues Will Likely Be Around $11 Billion By Next Year

Bristol-Myers Squibb's (NYSE:BMY) oncology business accounts for over 65% of the company's valuation, according to our estimates. The segment has seen strong sales growth in the recent years, primarily led by Opdivo, which is the one of the top selling drug in the immuno-oncology space, and will...